Europital launches as a science-driven full service CRO
Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries Ghent (Belgium), 22…
Former Biogen CFO Capello scores $2.6M payment plus full severance benefits on his way out
After bringing in a new CFO this summer—and as it navigates a turbulent stretch—Biogen is giving former chief finance officer Jeff Capello a multimillion-dollar…
Fujifilm’s flu drug Avigan improves COVID-19 recovery time, setting up filing in Japan
Six months after the World Health Organization declared COVID-19 a global pandemic, the list of drugs with proven efficacy against the…
Europe progressing in COVID-19 vaccine supply talks with Novavax: report
Having struck COVID-19 vaccine supply deals with AstraZeneca and the partnership between Sanofi and GlaxoSmithKline, European officials are advancing in talks with…
With U.S. elections nearing, European pharma giants brace for potential pricing action
With U.S. presidential and congressional campaigns in full swing, it’s not just Americans anxiously awaiting the results of the upcoming elections. The…
Sun Pharma the latest to recall metformin after carcinogen tests come up positive
Once cleared by the FDA of a probable carcinogen, generic diabetes med metformin has now been the target of a…
ICER rubber-stamps Vertex’s $311K CF drug Trikafta but blasts ‘monopoly’ pricing
No one disputes the therapeutic value of Vertex Pharmaceuticals’ triplet drug Trikafta for cystic fibrosis—not even the cost watchdogs at…
Rutgers scientists develop drug-infused ‘nanoscaffolds’ to fight inflammation at the source
Scientists at Rutgers University say they’ve developed a smart drug delivery system that fights inflammation at the site of spinal…
J&J wants everyone to know that taking care of their health can’t wait—even during a pandemic
Saying that a global pandemic is having a negative effect on people’s health seems obvious. However, along with direct cases…
How will BMS’ new Opdivo-Cabometyx kidney cancer combo fare against Keytruda? It may come down to marketing
When Bristol Myers Squibb this weekend unveiled a new trial win for an Opdivo combo in kidney cancer, industry watchers’…